Collagen Is the Wall, Not the Paint | The Angry Gut, Chapter 7

Orthostatic intolerance · hypermobility

Orthostatic Intolerance in Hypermobility: A Primary Care Screen

Orthostatic intolerance affects 35.9% of patients with hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder in pooled data, so every hypermobile patient warrants a screen. Autonomic nervous system testing and cardiac autonomic reflex tests measure it, with results returned to the ordering physician.

Hypermobile patients arrive with normal GI workups and decades of symptoms. The orthostatic and autonomic burden that travels with the diagnosis is common, measurable and usually undocumented.

Orthostatic intolerance is one of the most common extra-intestinal findings in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder, and one of the least often measured in practice. These patients usually arrive through a gastroenterology or rheumatology door with a normal workup and a long history. The collagen biology is laid out in Collagen Is the Wall, Not the Paint, a chapter video for The Angry Gut (Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes). For the treating physician the useful questions are operational: which comorbidities to screen for, which red flags change the referral, and how autonomic, balance and body-composition measurement fits a primary care workflow.

What conditions travel with hypermobility beyond the gut?

A 2026 meta-analysis pooled gastrointestinal and extra-intestinal data in this population. Chronic gut symptoms carried an odds ratio of 4.29 against controls; nearly two thirds, 65.3%, had one or more chronic gut complaints, and 44.2% fulfilled diagnostic criteria for a disorder of gut-brain interaction. The leading gut findings were upper tract: reflux at 41.3%, heartburn at 34.7%, functional dysphagia at 34.2%.

The extra-intestinal tail is where screening matters. Pooled prevalence ran 49% for chronic fatigue, 35.9% for orthostatic intolerance, 38.2% for migraine and 27.9% for fibromyalgia. Postural tachycardia pooled at 21.9%, but its interval of 5.2% to 59.1% makes the point estimate nearly useless for counseling. A global survey adds self-reported dysautonomia in 71.4%, chronic pain in 98.9%, a mean of 24 comorbid conditions and a mean diagnostic delay of 22.1 years. Survey data are self-selected, but a 22-year delay describes a care model, not a rare disease.

What the motility data argue

If lax collagen simply produced a lax bowel, manometry should show it. In 239 consecutive symptomatic patients undergoing antroduodenal manometry, 50 with hypermobility and 189 without, overall dysmotility and delayed gastric emptying did not differ, and enteric dysmotility turned up in 13% of hypermobile patients versus 34% of the others (p = 0.006). It is a single-unit research letter without a healthy comparison group. It still shifts the question. When the bowel moves normally and the patient remains symptomatic, the autonomic and orthostatic burden deserves a measurement before another GI study is ordered.

My own error belongs here. I used to think of the intestinal lining as a construction site: deliver the protein and the wall goes up. The pediatric enteropathy trials, where feeding barely moved biomarkers or growth, proved that model incomplete. Raw material is necessary, and a lining under sustained attack, the first brain running on metaflammation, does not rebuild on supply alone.

Red flags that change the referral

Vascular features. Vascular Ehlers-Danlos arises from a type III procollagen defect. In the classic cohort, bowel rupture accounted for about a quarter of complications, a quarter of patients had a first complication by age 20, and median survival was 48 years. Hypermobility with arterial or bowel events is not a primary care screening problem.
New malabsorption with a medication change. In collagenous sprue, where drug exposure was documented, 30 of 38 cases involved a medication tied to sprue-like injury, most often an angiotensin receptor blocker, and 37 of 50 improved on repeat biopsy. Read the medication list before labeling a small-bowel finding idiopathic.
A casual supplement plan in a sick patient. Among 1,223 ICU patients with multiorgan failure randomized in a glutamine trial, mortality at 28 days was 32.4% with glutamine and 27.2% without. That signal belongs to intensive care, but it argues against treating amino acid products as harmless in unwell patients.

How is orthostatic intolerance measured, and what does each finding change?

Measura [Cardiometabolic and Autonomic Health Analysis] has no connective-tissue assay and does not diagnose hypermobility disorders or postural tachycardia. It measures the regulatory and compositional consequences, with results returned to the ordering physician.

Autonomic nervous system testing and cardiac autonomic reflex tests document heart rate and blood pressure responses to standardized maneuvers, including postural change. An abnormal response supports referral and orthostatic counseling; a normal one redirects the workup.
Heart rate variability gives a repeatable index of autonomic balance for follow-up.
Vestibular and balance testing converts symptomatic orthostasis into a documented fall-risk finding.
Bioimpedance body composition quantifies the muscle compartment. In a review of randomized trials of collagen hydrolysate, muscle outcomes were inconsistent and mostly positive only with exercise, so a low lean mass argues for loading and adequate protein rather than a powder.

Pair the measurements with a dietary protein estimate. The bowel-rest data are the human anchor: 14 days of parenteral feeding thinned the mucosa from 645 to 512 microns, and permeability lagged behind structural recovery after refeeding. Isolation, poor dentition and low appetite remove protein quietly, and none of them appears on a panel.

Documentation and workflow

Hypermobile patients accumulate referrals without a coordinating record. A standing order can attach an orthostatic symptom screen, autonomic testing and balance testing to a documented hypermobility diagnosis or a chronic unexplained upper-GI complaint with a normal structural workup. Fall-risk and functional findings belong in the annual wellness visit, and the pairing with falls work is described in cognitive assessment and fall prevention. Where results enter the chart is covered in getting results into the record. The full evidence file sits in the companion deep dive for The Angry Gut, and the patient explanation is EDS and POTS for patients. For the gastric absorption side, see intrinsic factor antibody screening.

Frequently asked questions

Which hypermobile patients should be screened for orthostatic intolerance?

Pooled prevalence of orthostatic intolerance is 35.9% in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder, high enough to justify asking every patient with a documented diagnosis. Prioritize those with chronic fatigue, presyncope, migraine, or persistent upper-GI symptoms despite a normal structural workup, and those reporting falls or near-falls. Review the selection criteria.

How reliable is the pooled POTS prevalence in hypermobility?

Not very. Postural tachycardia pooled at 21.9%, but the interval ran from 5.2% to 59.1%, which makes the point estimate close to useless for counseling an individual patient. Survey figures such as 71.4% dysautonomia are self-reported. The practical answer is to measure autonomic responses in the patient in front of you rather than rely on a population rate. See guidance on interpreting the report.

Does gastrointestinal dysmotility explain gut symptoms in hypermobile patients?

Less often than expected. In a manometry series of 239 symptomatic patients, enteric dysmotility appeared in 13% of hypermobile patients versus 34% of the rest, with no difference in delayed gastric emptying. The dominant complaints are reflux, heartburn and functional dysphagia. That pattern argues for evaluating autonomic and orthostatic contributors before repeating motility studies. Read about specialty applications.

When should hypermobility prompt concern for vascular Ehlers-Danlos syndrome?

When there is a history of arterial, bowel or organ rupture, or a family history of it. In the classic vascular cohort, bowel rupture made up about a quarter of complications, a quarter of patients had a first complication by age 20, and median survival was 48 years. Those patients need specialist and genetic evaluation, not a primary care screening pathway. Read the clinical rationale.

Can Measura results substitute for a POTS or connective-tissue diagnosis?

No. Measura does not assess collagen and does not diagnose. Autonomic, heart rate variability, balance and body composition results give the treating physician objective data on regulation, fall risk and muscle, which support referral decisions, counseling and follow-up. Diagnosis remains a clinical judgment made with the history, examination and any specialist testing. See more physician questions.

How is orthostatic intolerance tested in hypermobile patients?

Autonomic nervous system testing and cardiac autonomic reflex tests document heart rate and blood pressure responses to standardized maneuvers, including postural change. An abnormal response supports referral and orthostatic counseling; a normal one redirects the workup. Heart rate variability gives a repeatable index for follow-up, and vestibular and balance testing turns symptomatic orthostasis into a documented fall-risk finding, with results returned to the ordering physician.

What is the difference between POTS and orthostatic intolerance in hypermobility?

Orthostatic intolerance is the broader complaint of symptoms on standing, pooled at 35.9% in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder. Postural tachycardia is one pattern within it, pooled at 21.9% with an interval of 5.2% to 59.1%. Because the population rates are this imprecise, recording each patient’s own heart rate and blood pressure response to posture is what separates the patterns.

Is orthostatic intolerance dangerous in hypermobile patients?

The routine danger is falls. Symptomatic orthostasis in a hypermobile patient is a fall-risk finding that belongs in the annual wellness visit, and balance testing documents it. The dangerous exception is vascular Ehlers-Danlos syndrome: hypermobility with a history of arterial, bowel or organ rupture needs specialist and genetic evaluation rather than a primary care screening pathway.

Add autonomic measurement to the hypermobility workup

Learn how the Measura protocol fits autonomic, balance and body composition testing into a practice’s screening and referral workflow.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Kulin, D., Holtmann, G., Fairlie, T., Staller, K., Nurko, S., Keefer, L., Drossman, D. A., Jones, M. P., Talley, N. J., & Ford, A. C. (2026). Meta-analysis: Chronic gastrointestinal symptoms and comorbidities in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders. Alimentary Pharmacology & Therapeutics, 64(5), 574–589. https://doi.org/10.1111/apt.70856
Daylor, V., Griggs, M., Weintraub, A., Byrd, R., Petrucci, T., Huff, M., Byerly, K., Fenner, R., Gensemer, C., Norris, R. A., & Patel, S. (2025). Defining the chronic complexities of hEDS and HSD: A global survey of diagnostic challenges, life-long comorbidities, and unmet needs. Journal of Clinical Medicine, 14(16), 5636. https://doi.org/10.3390/jcm14165636
Sweerts, K. W. E., Mujagic, Z., Keszthelyi, D., & Conchillo, J. M. (2025). Analysis of antroduodenal motility in patients with hypermobility spectrum disorders/hypermobile Ehlers-Danlos syndrome. Alimentary Pharmacology & Therapeutics, 61(4), 702-705. https://doi.org/10.1111/apt.18471
Pepin, M., Schwarze, U., Superti-Furga, A., & Byers, P. H. (2000). Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. The New England Journal of Medicine, 342(10), 673–680. https://doi.org/10.1056/NEJM200003093421001
Stirrat, T., Wilkey, M., Kim, S., Waterman, A., & Mattar, M. (2026). Collagenous sprue across five decades (1970-2025): A systematic review. Scandinavian Journal of Gastroenterology, 61(5), 577–585. https://doi.org/10.1080/00365521.2026.2641509
Heyland, D., Muscedere, J., Wischmeyer, P. E., Cook, D., Jones, G., Albert, M., Elke, G., Berger, M. M., & Day, A. G. (2013). A randomized trial of glutamine and antioxidants in critically ill patients. The New England Journal of Medicine, 368(16), 1489–1497. https://doi.org/10.1056/NEJMoa1212722
Brueckheimer, P. J., Costa Silva, T., Rodrigues, L., Zague, V., & Isaia Filho, C. (2025). The effects of type I collagen hydrolysate supplementation on bones, muscles, and joints: A systematic review. Orthopedic Reviews, 17, 129086. https://doi.org/10.52965/001c.129086
Buchman, A. L., Moukarzel, A. A., Bhuta, S., Belle, M., Ament, M. E., Eckhert, C. D., Hollander, D., Gornbein, J., Kopple, J. D., & Vijayaroghavan, S. R. (1995). Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. JPEN. Journal of Parenteral and Enteral Nutrition, 19(6), 453–460. https://doi.org/10.1177/0148607195019006453
Rachmadi, R. A., Ariani, Y., & Alatas, F. S. (2024). Impact of nutritional supplementation on environmental enteric dysfunction (EED) in children living in rural areas: A systematic review. Arquivos de Gastroenterologia, 61, e23159. https://doi.org/10.1590/S0004-2803.24612023-159